Latest Revenue Growth News

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

IDT Australia reports a robust 30% jump in quarterly revenue to $4.1 million, driven by strong contract wins and a $62 million pipeline of open proposals, signaling sustained growth in pharmaceutical manufacturing.

Vitasora Health Limited reports a striking 101% revenue increase and 57% patient growth in Q1 2025, driven by new Medicare Shared Savings Plan contracts and significant operational efficiencies from its Orb Health merger.

Alexium International Group reported a challenging Q3 FY2025 with lower revenues due to softness in the US bedding market, while making significant technological strides and maintaining a solid funding position.

Streamplay Studio Limited reported a remarkable 827% increase in customer receipts for Q3 2025, driven by the full integration of Noodlecake Studios. With a robust cash balance of A$7.7 million and no debt, the company is well-positioned to accelerate growth across cloud gaming, game publishing, and emerging markets.

Pact Group Holdings reports a modest 2.7% revenue increase for Q3 FY25, driven by higher volumes and cost savings, while preparing to refinance debt and review its Asian packaging business.

QuickFee Limited reported a 29% rise in Q3 FY25 revenue, driven by strong growth in its finance products and Connect platform. However, a significant US credit impairment has prompted a downward revision of its FY25 statutory earnings guidance.

Resonance Health reports record $14.9M cash receipts over 12 months and completes cost-cutting measures while advancing two major pharma clinical trials on schedule.

ReadCloud reports robust first half FY25 results, driven by a standout 29% revenue increase in its VET-in-Schools segment, alongside positive cash flow and strengthened operating leverage.

Way2VAT Ltd reported a robust 54% increase in Q1 FY25 revenue to A$1.05 million, driven by new client onboarding and higher VAT claim volumes, alongside strategic cost reductions and fresh credit facilities.

Vection Technologies has successfully raised $3.55 million, exceeding its initial $2 million target, following a robust Q3 FY25 performance marked by a 92% increase in cash receipts and a significant boost in recurring revenue.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.